Efferon, a startup featured in TechCrunch Disrupt 2026’s Startup Battlefield 200, aims to reduce the impact of pediatric sepsis through innovative blood-purification technology. Their device, Efferon NEO, is tailored for children, addressing the unique physiological needs of young patients to lower organ failure rates and enhance recovery times.
While Efferon is not expanding as rapidly as some tech companies, its focus remains on the critical outcome of improving children's health, emphasizing that success is measured by the number of children who recover and return home.
Efferon's focus on pediatric sepsis treatment highlights a critical gap in child healthcare. As they refine Efferon NEO, watch for clinical trial results that could validate its effectiveness, potentially influencing pediatric care protocols and attracting further investment.